As of November 6, 2026, Revelation Biosciences, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on August 19, 2026 (Form 8-K, August 19, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Revelation Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Revelation Biosciences, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-08-19. Every row below is cited to the filing it comes from, and this page adds each new change as Revelation Biosciences, Inc. files it.
Also on the record for Revelation Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 7.8% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| January 20, 2026 | Stake report, Schedule 13G, by SABBY MANAGEMENT, LLC | 9.6% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| May 23, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| May 20, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
Selling to them or working with them? See who runs Revelation Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Revelation Biosciences, Inc. and the records around it.
Revelation Biosciences, Inc. elsewhere on the record
Companies that share a holder
- SABBY MANAGEMENT, LLC also filed stake reports on 15 other companies: Globavend Holdings Ltd (Jan 2026), Jiuzi Holdings, Inc. (Jan 2026), Tempest Therapeutics, Inc. (Jan 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Revelation Biosciences, Inc.
Get an email when Revelation Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Revelation Biosciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Revelation Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Revelation Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-19 | Reported | not named in the filing | 8-K, 2026-08-19 |
New leaders reset buying decisions — get the Full Report on Revelation Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Revelation Biosciences, Inc., with the record behind each one.
Find candidates like senior executive at Revelation Biosciences, Inc.Every change, in the filing's words
Reported
Unless otherwise provided in the 2021 Plan or an individual agreement, unvested shares will be forfeited upon a termination of service for any other reason, including for Cause, Disability, or Retirement (as such terms are defined in the 2021 Plan).
- On August 17, 2026, the Compensation Committee of the Board of Directors (the "Compensation Committee") of Revelation Biosciences, Inc. (the "Company") approved grants of restricted shares of the Company's common stock (the "Restricted Stock Awards"), including to James Rolke, the Company's Chief Executive Officer, and Chester S. Zygmont, III, the Company's Chief Financial Officer, pursuant to the Revelation Biosciences, Inc. Amended and Restated 2021 Equity Incentive Plan (the "2021 Plan").
- The Restricted Stock Awards were granted effective August 17, 2026.
- Mr. Rolke received a Restricted Stock Award covering 208,076 shares of the Company's common stock, and Mr. Zygmont received a Restricted Stock Award covering 208,073 shares of the Company's common stock.
- For these purposes, market capitalization is determined by multiplying the closing sale price of the Company's common stock on the principal exchange by the number of shares of common stock outstanding as of the close of business on that trading day.
- The Restricted Stock Awards will become fully vested immediately before (and contingent upon the consummation of) a Change in Control (as defined in the 2021 Plan), except as otherwise provided in an individual agreement between the Company and the applicable executive.
Tools for this story
Each opens in a new tab, filled in for Revelation Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.